Author: Angelo Ramessar

Sameera Tak Facing Biosimilar Competition: Value & Access Readiness Strategies Sameera Tak Biosimilars Loss of exclusivity is notorious for giving pharma and biotech executives sleepless

GAVIN OUTTERIDGE How biopharma innovators can benefit from the ACCESS Consortium and CAN/UK/AUS collaboration in HTA GAVIN OUTTERIDGE & BOB CLAY What’s happening now, across

GAVIN OUTTERIDGE The European Union’s new Health Technology Assessment (HTA) Regulation demands that innovative biotech and pharma companies submit a new type of value dossier